Recombinant Human FGF-21 #abs00886

abs00886-5ug

1-2 Weeks

138

abs00886-25ug

1-2 Weeks

344

abs00886-1mg

1-2 Weeks

3891

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and subsequently lyophilized.

Properties

aa_sequence

TAGGGPSLSPD SVVGTKVLRL HEPLDPQAAE AHGVIERDTL ADGSPEAQDK QLLLKQKAPL IIGSQWLPKV TGKFQRPLCQ HGAIYLYEFD EPEFSDRLLR GVYPENQDAS AHHGLLPPLG DKPSHPRPAG LRAPLPGPAL LPPALPQMGP DMPGPSLPGV GSSAPEQRYS ASPHDQRGSN VPGVSPAMSK SPLHRGHLFR DDLAHTLLPA GGIQAQQETS DGTSPEQGSL LYPLRSTQPD HHGAAAS^

Concentration

> 96 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method determined that Recombinant Human FGF-21 contains less than 1 EU/μg. A similar statement can be created by rephrasing the original text, such as: Based on the LAL method, the Recombinant Human FGF-21 has been found to have a presence of less than 1 EU/μg.

Activity

When compared to the standard, the ED has been found to be fully biologically active. This means that it has the same level of activity as the standard.₅₀The specific activity of the tested compound was found to be greater than 2.0 × 10, as determined by a thymidine uptake assay using FGF-receptors transfected BaF3 cells. The concentration of the compound required to achieve this activity was less than 0.5 μg/ml. These findings suggest that the tested compound may have potent effects on cellular proliferation and warrant further investigation.³In the presence of 5 µg/ml of rMuKlotho-β and 10 μg/ml of heparin, the activity was measured as IU/mg. Let's rearrange the given content to provide a highly similar but rephrased version: The measurement of activity, expressed as IU/mg, was conducted in the presence of 5 µg/ml of rMuKlotho-β and 10 μg/ml of heparin.

Reconstitution

To ensure that the contents are properly mixed, we suggest a quick spin in the centrifuge prior to opening the vial. In order to reconstitute the substance, please use either sterile distilled water or an aqueous buffer containing 0.1% BSA, and create a concentration of 0.1-1.0 mg/mL. Any unused solution should be divided into smaller aliquots and stored at temperatures at or below -20°C. For further dilutions, it is recommended to use appropriate buffered solutions.

Stability & Storage

To maintain the stability of this lyophilized preparation, it is recommended to store it at 2-8 °C. However, for long-term storage, it is best to keep it at -20 °C, and even better if desiccated. Once reconstituted, the preparation can last for up to one week at 2-8 °C. For optimum stability, it is recommended to divide the reconstituted preparation into working aliquots and store them at temperatures ranging from -20 °C to -70 °C. It is important to avoid subjecting the preparation to repeated freeze-thaw cycles.

Target

Accession

Q9NSA1

Gene IDs

26291

References

References

1. Nishimura T, Nakatake Y, Konishi M, et al. 2000. Biochim Biophys Acta. 1492:203-6.

2. Kharitonenkov A, Shiyanova TL, Koester A, et al. 2005. J Clin Invest. 115:1627-35.

3. Kurosu H, Choi M, Ogawa Y, et al. 2007. J Biol Chem. 282:26687-95.